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ernment, even if not by all its 
backbenchers). Though partly ide-
ological, such support reflects the 
steady annual improvements in 
the NHS’s effectiveness and safety 
seen in recent years. And third, 
turmoil provides an opportunity 
for innovation. It can produce 
collective efforts in which fac-
tional interests are set aside and 
long-standing controversial issues, 
such as bringing health care and 
social services closer together 
(even by combining their budgets 
into one), are finally addressed.
Although some of the chal-
lenges in England are unique, 
the underlying problem of meet-
ing rising demand for care with 
steady or diminishing resources 
is faced by many countries. Just 
as we can learn from other health 
care systems, our experiences over 
the next few years in redesigning 
the organization and delivery of 
services will undoubtedly provide 
lessons for others.
Disclosure forms provided by the author 
are available with the full text of this arti-
cle at NEJM.org.
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Research and Policy, London School of Hy-
giene and Tropical Medicine, London.
This article was published on June 19, 2013, 
at NEJM.org.
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Can England’s NHS Survive?
NICE: Moving Onward
Michael D. Rawlins, M.D.
The National Institute for Clin-ical Excellence (NICE) was es-
tablished in 1999, primarily to 
offer professionals in Britain’s 
National Health Service (NHS) 
advice on providing care that 
meets the highest attainable stan-
dards. NICE’s role was expanded 
in 2005 to include provision of 
analogous advice to the broader 
public health community on pre-
venting ill health and maintain-
ing good health. (The name was 
changed to the National Institute 
for Health and Clinical Excellence, 
but the acronym NICE has con-
tinued to be used.)
To meet these objectives, NICE 
now has three different strands 
of responsibilities (see table),1 and 
its budget from the government 
has increased tenfold. Much atten-
tion, however, continues to focus 
on NICE’s technology appraisals 
and clinical-guideline programs.
Since 2000, the Institute has 
been publishing technology ap-
praisals — assessments of the 
clinical effectiveness and cost-
effectiveness of (mainly) new phar-
maceutical products, including 
whether providing them consti-
tutes a good use of NHS resourc-
es. Contrary to popular mythology, 
NICE rejects less than 15% of 
technologies on the grounds of 
cost-ineffectiveness. In recent 
years, manufacturers have increas-
ingly been offering the NHS, 
through NICE, “patient access 
schemes,” which can substantial-
ly reduce the price of products 
and render them more likely to 
be considered cost-effective. Such 
offers have sometimes led a prod-
uct with a negative provisional 
assessment to gain a positive final 
one, and occasionally decisions 
have been reversed because man-
ufacturers have submitted addi-
tional evidence about a product’s 
clinical effectiveness.
NICE’s clinical guidelines im-
prove the quality of care provid-
ed to NHS patients. For example, 
after the publication of a guide-
line on the prophylactic use of 
antibiotics in patients with me-
chanical cardiac lesions, the vol-
ume of prescriptions by dental 
surgeons fell by more than 80% 
in 6 months.2 Similarly, as a re-
sult of a guideline on preventing 
venous thromboembolism, the rate 
of risk assessments in patients 
admitted to NHS hospitals in-
creased from less than 40% in 
2010 to 94% in 2012.3 Not all 
NICE’s clinical guidelines have 
had such an effect: the Institute’s 
guidance on managing infertili-
ty, including the use of in vitro 
fertilization, was fully adopted by 
only about 25% of primary care 
trusts (the regional administrative 
bodies that, until recently, com-
missioned and provided health 
care services to NHS patients).
NICE distinguishes clinical 
guidelines defining optimal care 
pathways for specific conditions 
from standards describing generic 
competencies for health care pro-
fessionals. Professional standards 
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may cover anything from treating 
patients with dignity and respect, 
to ways of avoiding bedsores, to 
the procedure for safely inserting 
a nasogastric tube. These stan-
dards are generally agreed to be 
the responsibility of the medical 
and nursing regulatory authori-
ties, the royal colleges and profes-
sional societies. The recent scan-
dal at Mid-Staffordshire Hospitals 
— where investigators found 
what were widely described as 
“appalling” conditions and care 
— was primarily attributable to 
failures in adhering to profession-
al standards.4
I believe that NICE has largely 
succeeded in its mission, thanks 
to four key ingredients. The first 
has been the political and fiscal 
environment. There is now wide 
acceptance that no country seek-
ing to provide universal health 
care has the resources necessary 
to achieve the highest possible 
standards of care for everyone. 
In 1999, when NICE was estab-
lished, there was limited, tacit 
acceptance of this gloomy fact. 
Fourteen years later, there is great-
er honesty among politicians and 
health policymakers, owing in 
part to the global financial crisis. 
Priorities must be set on the ba-
sis of evidence of both clinical ef-
fectiveness and cost-effectiveness.
However, priority setting in 
health care must encompass more 
than the technical and scientific 
demands of health technology 
assessment. It must also take ac-
count of the social values of the 
relevant communities. NICE there-
fore established a Citizens Coun-
cil, with members drawn from 
the general public, to examine, 
deliberate over, and report on the 
social principles on which the In-
stitute’s guidance should be 
based.5 Health care systems else-
where need to develop their own 
approaches to eliciting social val-
ues, which won’t necessarily re-
flect the culture and preferences 
of the British public.
Second, NICE has adopted a 
methodologically rigorous ap-
proach to guidance development. 
All NICE guidance is based on a 
full systematic review of the 
available evidence, including not 
only the results of randomized, 
controlled trials, but also obser-
vational and analytic studies. In-
formation on the Institute’s pro-
cesses and methods is publicly 
available, and these processes 
undergo revisions every 3 years.
The World Health Organization 
has reviewed them twice and 
found, overall, that NICE guid-
ance is developed to the highest 
standards.
The third factor is inclusivity. 
The Institute has strived to in-
volve its stakeholders — health 
care professionals, patients and 
their representative organizations, 
and relevant life-sciences compa-
nies — in all its programs. All 
NICE: Moving Onward
NICE’s Current Responsibilities.
Guidance programs
Technology appraisals Decisions about use of mainly new health technologies in the National Health Service (NHS) based 
on their clinical effectiveness and cost-effectiveness
Clinical guidelines Advice on management of specific clinical conditions based on clinical effectiveness and cost-effec-
tiveness
Interventional procedures Determinations of whether mainly new interventional procedures are sufficiently safe and effective for 
use in the NHS
Public health Guidance about disease prevention, health improvement, and health protection for both the NHS 
and local government
Medical technologies Decisions about use of cost-saving medical technologies in the NHS
Diagnostic agents Decisions about use of mainly new in vivo and imaging methods in the NHS based on clinical effec-
tiveness and cost-effectiveness
Performance standards and metrics
Quality Outcomes Framework Menu of clinical indicators for inclusion in the NHS contract with family doctors
Quality standards Key performance indicators in specific areas to which a high-performing institution should aspire
Clinical Commissioning Group 
Outcome Indicators
Key indicators for measuring health outcomes for services commissioned mainly by professional 
groups (predominantly comprising general practitioners) called Clinical Commissioning Groups
Information services
NHS Evidence Online search engine identifying reliable sources of material relevant to a particular clinical problem
NICE Pathways Totality of NICE guidance, in algorithmic form, about a particular topic or condition (available as 
apps for iPhones, iPads, and Android devices)
Medicines Management Evidence summaries for new medicines not undergoing technology appraisal
Evidence regarding unlicensed and off-label use that is not included in a guideline
Good practice advice (e.g., on the construction of local hospital formularies)
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stakeholders are invited to con-
tribute to revisions of our process-
es and methods and encouraged 
to submit evidence on particular 
topics for consideration by the 
Institute’s advisory bodies.
All NICE’s clinical-guideline 
groups include at least two pa-
tients (or “service users”), except 
in the case of guidelines for chil-
dren’s illnesses, in which we in-
clude the parents of children with 
the condition in question. Because 
meeting with distinguished clini-
cians can be daunting, NICE pro-
vides participating service users 
with specific training for their role.
The Institute’s stakeholders 
have been generally (though not 
uncritically) supportive. Despite a 
rocky beginning with the life-
sciences industry and particular-
ly the pharmaceutical industry, 
relations improved as it became 
clear that we supported the use of 
most new drugs but that health 
care systems globally can afford 
only cost-effective products.
Fourth, NICE has, from the out-
set, jealously guarded its inde-
pendence from vested interests, 
whether government, the profes-
sions, patient organizations, or the 
life-sciences industries. Govern-
ment ministers formally refer spe-
cific appraisal, clinical-guideline, 
and public health topics to the In-
stitute for development. At first, 
Department of Health officials se-
lected topics for approval by gov-
ernment ministers, but now NICE 
proposes topics for referral by 
ministers, and then guidance con-
tent becomes entirely the respon-
sibility of the Institute and the 
relevant advisory body. Ministers 
do not attempt to influence NICE 
guidance and have never threat-
ened to overturn any of NICE’s 
advice.
All NICE guidance is devel-
oped by independent members of 
advisory bodies, who are drawn 
from the NHS and British univer-
sities. The Institute’s board can 
suppress a piece of guidance that 
it believes to be flawed, but it has 
never had to exercise this option. 
From the outset, the Institute 
has had strict conflict-of-interest 
rules covering both its staff and 
advisory-body members.
NICE is now a permanent com-
ponent of the British health care 
environment, having been reestab-
lished on April 1, 2013, in legisla-
tion that also requires the Institute 
to develop guidelines and perfor-
mance metrics for social services. 
This change, I hope, will help im-
prove the integration of Britain’s 
health care and social services, 
whose interactions have too often 
been dysfunctional. (With this ad-
dition to its remit, the Institute’s 
name has been changed again, to 
the National Institute for Health 
and Care Excellence.)
NICE’s experience may carry 
lessons for the United States, 
which has an abundance of the 
technical, scientific, and clinical 
skills needed to develop robust 
guidance for clinical practice — 
but which appears, at least to an 
outsider, to lack the political will 
to ensure the provision of universal 
health care and to accept that in 
so doing it will have to set priori-
ties. The Affordable Care Act takes 
a modest step in this direction, but 
the current level of expenditure on 
health care in the United States is 
unsustainable. If the United States 
is to meet the needs of all its citi-
zens, especially in the face of an 
increasingly elderly population, it 
will someday have to take both 
clinical effectiveness and cost-ef-
fectiveness into account in deter-
mining the contents of its pack-
age of universal health care. Our 
experience in the United Kingdom 
shows that, though sometimes un-
comfortable, it is possible.
Disclosure forms provided by the author 
are available with the full text of this article 
at NEJM.org.
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From Imaging Gatekeeper to Service Provider —  
A Transatlantic Journey
Saurabh Jha, M.B., B.S.
In Britain, where I trained in surgery, residents feared radi-
ologists. One radiologist was nick-
named “Dr. No,” since his first 
response was always to deny re-
quests for any imaging other 
than a plain radiograph. We had 
no computerized order-entry sys-
tem, so after rounds, the junior 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on January 21, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
